Tvardi Therapeutics (TVRD) Amortization of Deferred Charges (2013 - 2024)
Tvardi Therapeutics (TVRD) posted Amortization of Deferred Charges of $241000.0 for Q3 2024, down 5.86% sequentially from $256000.0 in Q2 2024, and down 47.84% YoY from $462000.0 in Q4 2023.
Tvardi Therapeutics (TVRD) Amortization of Deferred Charges (2013 - 2024) Analysis & Trends
Tvardi Therapeutics has reported Amortization of Deferred Charges for 4 years, with the latest figure at $241000.0 in Q3 2024.
- Quarterly Amortization of Deferred Charges fell 47.84% year-over-year to $241000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2024 was $766000.0 (down 63.08% YoY) and the FY2024 annual result came in at $766000.0, down 63.08% from the prior year.
- Amortization of Deferred Charges eased to $241000.0 in Q3 2024 per TVRD's latest filing, from $256000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $854000.0 in Q4 2023 and troughed at $241000.0 in Q3 2024.
- A 3-year average of $401000.0 and a median of $371000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges jumped 132.7% in 2023, then slumped 47.84% in 2024.
- Over 3 years, Amortization of Deferred Charges stood at $367000.0 in 2022, then surged by 132.7% to $854000.0 in 2023, then tumbled by 71.78% to $241000.0 in 2024.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $241000.0, $256000.0, and $269000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 241,000.00 |
| Sep 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Mar 31, 2024 | 269,000.00 |
| Mar 31, 2024 | 269,000.00 |
| Dec 31, 2023 | 854,000.00 |
| Dec 31, 2023 | 854,000.00 |
| Sep 30, 2023 | 462,000.00 |
| Sep 30, 2023 | 462,000.00 |
| Jun 30, 2023 | 384,000.00 |
| Jun 30, 2023 | 384,000.00 |
| Mar 31, 2023 | 375,000.00 |
| Mar 31, 2023 | 375,000.00 |
| Dec 31, 2022 | 367,000.00 |
| Dec 31, 2022 | 367,000.00 |
| Sep 30, 2013 | 39,000.00 |
| Sep 30, 2013 | 39,000.00 |
| Jun 30, 2013 | 59,000.00 |
| Jun 30, 2013 | 59,000.00 |